Diabetes

The top stories in managed care this week include findings on cancer survival disparities, CVS Health claimed drug spending growth slowed in 2015, and Horizon Blue Cross Blue Shield of New Jersey's OMNIA plan is interfering with existing patient-centered medical homes.

Mann spent $1 billion of his own money to bring Afrezza to market. The Los Angeles Times reported he died in Las Vegas.

A new proposal from researchers at MIT and Dana-Farber offers a remedy for patients to cover high healthcare costs: securitized consumer healthcare loans.

Unlike former Mayor Michael Bloomberg's attempt to limit soda portions, this rule gives consumers information and lets them make their own decisions. Such measures have had more support from the public and the courts.

A report from The Food Trust offers ideas and case studies on how to get fruits and vegetables to the customers who historically have had less access to them.

The full slides from the 2015 Patient-Centered Diabetes Care keynote speech, where Robert A. Gabbay, MD, PhD, discussed new care models being implemented to improve patient health in the long term.

BMJ's study found no link bewteen incretin-based drugs and pancreatic cancer but said because of the latency of the cancer, adverse effects would have to be watched.

Pollution is believed to create insulin resistance and chronic inflammation, which leads to obesity and diabetes.

The state's first-of-its-kind model for delivering Medicaid creates brings managed care concepts without commercial insurers to the one of the nation's poorest markets.

Adult obesity increased to 28% of the US population in 2015 and the diabetes rate also climbed to 11.4%. Adults who are obese are 4.7 times more likely to be diabetic compared with adults with a normal weight

This week's top managed care stories included the release of 7 core sets of quality measures, more evidence that value-based insurance design works to lower costs, and the FDA assigns breakthrough designation to AstraZeneca's PD-L1 inhibitor.

The scientists on the panel will advise JDRF on policy and research priorities as the organization supports major initiatives to cure type 1 diabetes or manage the disease.

FDA had halted work on the study drug after 2 deaths in an unrelated trial.

The clinical trial across 3 sites in California and Washington state will involve 300 participants and report results in 2017.

Individuals with more than one diagnosis are more likely to report to a primary care physician than to a subspecialty physician.

Deploying the algorithm in EHRs on a widepread basis could help find up to 400,000 Americans with undiagnosed diabetes, the researchers say.

This study identified 4 distinct medication adherence trajectories and found that continuity of care was consistently associated with medication adherence in every trajectory group.

There are 2 dimensions to patient centeredness of diabetes care that Lonny Reisman, MD, the founder and chief executive officer of HealthReveal, will focus on during his keynote speech at Patient-Centered Diabetes Care 2016.

The authors conclude that being overweight is not without risk, and their findings come after other estimates see the burden of chronic kidney disease increasing in the United States.

The results amplify earlier work at UAB that showed verapamil reversed type 1 diabetes in mice. A clinical trial involving the drug in recently diagnosed patients with type 1 disease is still enrolling participants.

The report on the Traditional Foods Project is part of CDC supplement on reducing healthcare disparities.

Using surgery to promote weight loss and improve health is associated with improve mortality. This study sought information on whether survival benefits extended to patients at higher ages.

The study, while small, suggests a scalable solution that would allow payers address diabetes prevention and health disparities.

Innovation has remained high on the administration’s agenda, as is evident from the allocations to tackle climate changes as well as find treatments for devastating health conditions.

Mexico is the perfect example of how Coke and Pepsi are investing heavily in the next generation of soda drinkers, and the country has the highest rates of obesity in the world.